BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 8306326)

  • 21. Alterations of the p53 tumor suppressor gene during mouse skin tumor progression.
    Ruggeri B; Caamano J; Goodrow T; DiRado M; Bianchi A; Trono D; Conti CJ; Klein-Szanto AJ
    Cancer Res; 1991 Dec; 51(24):6615-21. PubMed ID: 1742735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth suppression mediated by transfection of p53 in Hut292DM human lung cancer cells expressing endogenous wild-type p53 protein.
    Cajot JF; Anderson MJ; Lehman TA; Shapiro H; Briggs AA; Stanbridge EJ
    Cancer Res; 1992 Dec; 52(24):6956-60. PubMed ID: 1458487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic alterations associated with the evolution and progression of astrocytic brain tumours.
    Ohgaki H; Schäuble B; zur Hausen A; von Ammon K; Kleihues P
    Virchows Arch; 1995; 427(2):113-8. PubMed ID: 7582239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas.
    Tohma Y; Gratas C; Van Meir EG; Desbaillets I; Tenan M; Tachibana O; Kleihues P; Ohgaki H
    J Neuropathol Exp Neurol; 1998 Mar; 57(3):239-45. PubMed ID: 9600216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
    Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
    Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TP53 mutations in malignant astrocytomas.
    Biernat W; Debiec-Rychter M; Kordek R; Liberski PP
    Pol J Pathol; 1997; 48(4):221-4. PubMed ID: 9529927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chromosomal instability and p53 inactivation are required for genesis of glioblastoma but not for colorectal cancer in patients with germline mismatch repair gene mutation.
    Leung SY; Yuen ST; Chan TL; Chan AS; Ho JW; Kwan K; Fan YW; Hung KN; Chung LP; Wyllie AH
    Oncogene; 2000 Aug; 19(35):4079-83. PubMed ID: 10962567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines.
    Reiss M; Brash DE; Muñoz-Antonia T; Simon JA; Ziegler A; Vellucci VF; Zhou ZL
    Oncol Res; 1992; 4(8-9):349-57. PubMed ID: 1486218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Mutations of p53 gene in 41 cases of human brain gliomas].
    Cui W; Kong X; Cao HL; Wang X; Gao JF; Wu RL; Wang XC
    Ai Zheng; 2008 Jan; 27(1):8-11. PubMed ID: 18184456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chromosome 17p deletions and p53 mutations in renal cell carcinoma.
    Reiter RE; Anglard P; Liu S; Gnarra JR; Linehan WM
    Cancer Res; 1993 Jul; 53(13):3092-7. PubMed ID: 8319216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53-dependent induction of WAF1 by cold shock in human glioblastoma cells.
    Ohnishi T; Wang X; Ohnishi K; Takahashi A
    Oncogene; 1998 Mar; 16(11):1507-11. PubMed ID: 9525749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas.
    Lang FF; Miller DC; Pisharody S; Koslow M; Newcomb EW
    Oncogene; 1994 Mar; 9(3):949-54. PubMed ID: 8108140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme.
    Marutani M; Tonoki H; Tada M; Takahashi M; Kashiwazaki H; Hida Y; Hamada J; Asaka M; Moriuchi T
    Cancer Res; 1999 Oct; 59(19):4765-9. PubMed ID: 10519380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay.
    Tada M; Iggo RD; Ishii N; Shinohe Y; Sakuma S; Estreicher A; Sawamura Y; Abe H
    Int J Cancer; 1996 Jul; 67(3):447-50. PubMed ID: 8707423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
    Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
    Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus.
    Zhang WW; Fang X; Mazur W; French BA; Georges RN; Roth JA
    Cancer Gene Ther; 1994 Mar; 1(1):5-13. PubMed ID: 7621238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic instability leads to loss of both p53 alleles in a human glioblastoma.
    Albertoni M; Daub DM; Arden KC; Viars CS; Powell C; Van Meir EG
    Oncogene; 1998 Jan; 16(3):321-6. PubMed ID: 9467957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional characterization in vivo of mutant p53 molecules derived from squamous cell carcinomas of the head and neck.
    Cardinali M; Kratochvil FJ; Ensley JF; Robbins KC; Yeudall WA
    Mol Carcinog; 1997 Feb; 18(2):78-88. PubMed ID: 9049183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma.
    Zhu Y; Guignard F; Zhao D; Liu L; Burns DK; Mason RP; Messing A; Parada LF
    Cancer Cell; 2005 Aug; 8(2):119-30. PubMed ID: 16098465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endothelial cells co-cultured with wild-type and dominant/negative p53-transfected glioblastoma cells exhibit differential sensitivity to radiation-induced apoptosis.
    Khodarev NN; Labay E; Darga T; Yu J; Mauceri H; Gupta N; Kataoka Y; Weichselbaum RR
    Int J Cancer; 2004 Mar; 109(2):214-9. PubMed ID: 14750172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.